WHO ICTRP trial
Study to evaluate the efficacy and safety of Paxil® Tablets in children and…
EUCTR2015-004905-17-Outside-EU/EEA · EU Clinical Trials Register
Key facts
| Trial ID | EUCTR2015-004905-17-Outside-EU/EEA |
|---|---|
| Public title | Study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder |
| Scientific title | A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder |
| Primary sponsor | GlaxoSmithKline Research & Development |
| Registry | EU Clinical Trials Register |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Japan |
| Conditions | Major Depressive Disorder;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] |
| Interventions | Trade Name: Paxil Product Name: Paroxetine Pharmaceutical Form: Tablet INN or Proposed INN: PAROXETINE CAS Number: 61869-08-7 Other descriptive name: PAROXETINE Concentration unit: mg milligram(s) Concentration type: equal Concentration… |
| Registration date | Mar 8, 2016 |
| Target size | 319 |
| Secondary IDs | PIR112487 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: